Bristol Myers Squibb believes LPA1 receptor inhibition is the best approach to meet the urgent need for well tolerated new pulmonary fibrosis treatment options that can improve symptoms and address the underlying cause of disease.
The development path for better idiopathic pulmonary fibrosis (IPF) treatments is strewn with failures but Bristol Myers Squibb Company is hoping for a more successful journey on the back of positive mid-stage data for the high dose of its lysophosphatidic acid receptor 1 (LPA1) antagonist.
The US major's high hopes are based on a Phase II study which involved 276 IPF patients who were treated...
In its Q2 update, Viking reported that Phase III trials of subcutaneous VK2735 are under way, and that it expects Phase II data for an oral formulation before year’s end.
The Danish medical dermatology specialist doubles boosts its sales force ahead of the launch of Anzupgo.
In this series of articles, we look at different mechanisms of actions beyond GLP-1s that could determine the obesity drug landscape in the coming years. First on our list – amylin receptor agonists, which analysts expect to grow into a $50bn market opportunity.
